Kura Oncology, Inc.’s Post

I'm excited to share another impactful study, titled "Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens", published in Haematologica Journal! This study from Universitätsklinikum Schleswig-Holstein explores a crucial aspect of acute myeloid leukemia treatment. 💡 Although immediate treatment initiation is standard for newly diagnosed AML, this study using TriNetX suggests that deferring therapy to assess comorbidities/risk factors does not negatively impact survival. Analysis of 855 patients (138 from SAL-registry and 717 from TriNetX) showed no significant survival difference between early and delayed treatment groups. Delaying venetoclax-based therapy can be a safe option with proper clinical monitoring. Read the full study here: https://lnkd.in/d6EfFNtr A big thank you to Dr. David Baden for his hard work and dedication! #LeukemiaResearch #Venetoclax #CancerResearch

In relapsed or refractory NPM1-m acute myeloid leukemia, FLT3 co-mutations are common (up to 49%)(1), and prognosis is poor. In this population, only 14% of patients treated with a FLT3 inhibitor achieve a complete remission.(2) KOMET-008 is a phase 1 trial studying ziftomenib, a menin inhibitor, in combination with the FLT3 inhibitor gilteritinib in patients with NPM1-m/FLT3 co-mutations. NPM1-m patients without a FLT3 co-mutation and KMT2A-r patients will receive ziftomenib in combination with FLAG-IDA or LDAC. ACTIVELY RECRUITING. Learn more: https://lnkd.in/e7ryAK59

KOMET-008 is actively recruiting for patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-008 is a Phase 1 study to assess the safety and recommended Phase 2 dose of ziftomenib in combination with gilteritinib (for patients with a FLT3 co-mutation), FLAG-IDA, or LDAC. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM

The KOMET-007 phase 1 study will assess the safety, tolerability, and antileukemic activity of ziftomenib combinations in patients with newly diagnosed or relapsed or refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. Newly diagnosed patients will be eligible for ziftomenib combined with standard induction cytarabine/daunorubicin (7+3) or venetoclax/azacitidine. Patients with R/R AML will be eligible for ziftomenib combined with venetoclax (NPM1-m cohort only) or venetoclax/azacitidine. KOMET-007 is ACTIVELY RECRUITING. Learn more: https://lnkd.in/g37mAZZq

Acute Myeloid Leukemia (#AML) is the most common acute leukemia affecting adults, and the development of targeted therapies is helping to improve treatment options for patients across molecularly defined subsets. At Servier, we're continuing to drive advancements in AML research as part of our ongoing commitment to improving the lives of patients. Learn more about AML: https://lnkd.in/eFA3_aYi

📢 For the treatment of Acute Lymphoblastic Leukemia, Philadelphia chromosome-positive (Ph+)! 🩸💪 In patients where other kinase inhibitors are not indicated, an oral dose of 45 mg of ponatinib once daily is recommended. This initial dose should be continued until there is a loss of response or unacceptable toxicity. It's important to note that if a response has not occurred within 3 months, discontinuation of the treatment should be considered. These dosing recommendations offer hope for patients with this specific type of leukemia. Remember, it's always crucial to consult with your healthcare provider for personalized advice and guidance. #LeukemiaTreatment #PhPositive #Ponatinib #OralDose #ResponseMonitoring #HealthcareProvider #PersonalizedCare #HopeForPatients

The KOMET-001 Phase 1b study has shown encouraging clinical activity of ziftomenib, a menin inhibitor, for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. Learn about KOMET-001 Phase 2, a registration-directed trial evaluating ziftomenib, at the 65th ASH Annual Meeting and Exposition (booth #2701) or https://lnkd.in/eEHcvHDp.

The CD33 protein is a marker of cancerous white blood cells, making it a potential target for immunotherapies in acute myeloid leukemia (AML) patients. 🎯 Every year, 20,000 individuals get diagnosed with AML in the U.S. These patients are usually treated with gemtuzumab ozogamicin; however, this therapy is ineffective in patients with a variant T allele. This antibody, designed by Jatinder Lamba, Ph.D., and her team from the University of Florida College of Pharmacy, enables immunotherapy in these patients. 🔬 License this anti-CD33 antibody for treating AML today. ▶️ https://lnkd.in/eQfvyN9P

#cancertherapies #Bcell selection and the development of #Autoantibodies Current B-cell depletion therapies have derived from a deeper understanding of B-cell biology and markers that define B-cell populations. The fact that autoreactive and autoAb-producing B-lineage cells are sustained and regulated by BCR and TLR signals and by survival factors such as #BAFF/BLyS has led to a number of drugs targeting B-cell-associated signaling pathways. B-cell survival requires tonic signals through the BCR that are mediated in part by the #Syk, #Lyn and #Btk protein tyrosine kinases and by #phosphoinositide3-kinase. Inhibitors for each of these kinases have been developed and used to successfully treat B-cell #cancers such as chronic lymphocytic leukemia, and are just beginning to be fully evaluated in patients with autoimmune diseases.

Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult The treatment of acute lymphoblastic leukemia (ALL) continues to evolve with the introduction of new agents to replace chemotherapy and improve outcomes. In this educational program, experts share their best practices for treating patients with ALL and then use a case-based format to review the latest data regarding management and discuss key clinical challenges. Register here: https://ow.ly/noAk50PwU2I #PER #PEROnline #PEROnlineActivities